PATENT CLAIM ANALYSIS

Application Number: 16211687
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "469000"]

Abstract:
Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).

Claim (Index 1):
A method of treating a sleep disorder in an individual suffering from Smith-Magenis Syndrome (SMS), the method comprising:\n inhibiting melatonin production in the individual during waking hours; and administering to the individual an effective amount of tasimelteon once daily before bedtime.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 98.0
- Lexical Diversity: 1.11111
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15326934', '15378353', '15822162', '14374257', '16180316']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6445282974450541
- 35 USC 102 Novelty (BERT): 0.518875673397032
- Combined Prediction Score: 0.631963035040252
- Mean Citation Score: 267.636208
- Max Citation Score: 307.86633
- Similarity Product: 260.6100531498832

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test